Actavis PLC (ACT): Today's Featured Health Care Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Actavis ( ACT) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 1.3%. By the end of trading, Actavis rose $9.81 (4.7%) to $220.37 on heavy volume. Throughout the day, 5,670,722 shares of Actavis exchanged hands as compared to its average daily volume of 1,636,700 shares. The stock ranged in a price between $210.49-$222.24 after having opened the day at $211.45 as compared to the previous trading day's close of $210.56. Other companies within the Health Care sector that increased today were: Ultragenyx Pharmaceutical ( RARE), up 17.1%, Raptor Pharmaceutical ( RPTP), up 14.9%, Biolase ( BIOL), up 12.4% and China Biologic Products ( CBPO), up 11.9%.

Actavis plc, an integrated specialty pharmaceutical company, develops, manufactures, markets, and distributes pharmaceutical products in the United States, Canada, and internationally. Actavis has a market cap of $35.1 billion and is part of the drugs industry. Shares are up 25.3% year to date as of the close of trading on Wednesday. Currently there are 10 analysts that rate Actavis a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Actavis as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity.

On the negative front, Onconova Therapeutics ( ONTX), down 36.6%, Cryolife ( CRY), down 12.6%, Aoxing Pharmaceutical Company ( AXN), down 11.5% and Cardiome Pharma Corporation ( CRME), down 9.7%.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Icahn Bets on Allergan's Brett Saunders in Post-Pfizer Era

What Bill Ackman's Voice Could Mean for the Valeant Board Room

What Bill Ackman's Voice Could Mean for the Valeant Board Room

Jim Cramer: There’s No Way We’ll See More Railroad M&A

Federal Reserve to Reassess Global Risks in Minutes on Wednesday

Can Allergan-Pfizer Survive Treasury's New Crackdown on Inversions?